Don’t let the high cost of brand chronic hepatitis B therapy disrupt your treatment. We help eligible patients access Vemlidy (tenofovir alafenamide) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Vemlidy Prescription Assistance Program is a manufacturer-sponsored initiative that provides Vemlidy at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for chronic hepatitis B patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, hepatologist or PCP coordination, prior-authorization documentation, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$1,650.00 | Save ~$1,580/mo |
| CVS Pharmacy | ~$1,700.00 | Save ~$1,630/mo |
| Walmart | ~$1,500.00 | Save ~$1,430/mo |
| Costco | ~$1,450.00 | Save ~$1,380/mo |
Generic TDF (alt) | ~$30.00 | Already low |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply for and provides Vemlidy at no medication cost if approved. Our $69.95/month service covers full advocacy. With generic tenofovir disoproxil fumarate (TDF) widely available at low cost as an alternative for HBV, we’ll help you and your provider determine the best path.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Vemlidy:
Still $1,400–$1,700 per month even with the best discount
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Vemlidy assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Vemlidy (tenofovir alafenamide, TAF, 25 mg) is a once-daily nucleotide reverse transcriptase inhibitor used to treat chronic hepatitis B in adults and pediatric patients ≥6 years and ≥25 kg. TAF is a tenofovir prodrug that achieves higher intracellular tenofovir levels with lower plasma exposures than the older TDF — translating to less kidney and bone toxicity.
How Vemlidy Works:
Hepatitis B virus (HBV) replicates in liver cells using a reverse transcriptase enzyme, which is blocked by inhibitors like Tenofovir alafenamide (TAF). As a prodrug, TAF is converted to its active form primarily inside liver cells, allowing for targeted delivery with less drug circulating in the bloodstream. This mechanism maintains strong antiviral activity while reducing exposure to the kidneys and bones compared to older treatments.
Form and use:
Vemlidy is administered as a single 25 mg tablet taken by mouth once daily with food. Because chronic HBV requires long-term management to prevent disease progression, patients typically remain on this therapy for many years. It is crucial not to stop treatment abruptly, as doing so can trigger a severe and acute worsening of the hepatitis B infection.
Generic availability:
As of 2026, there is no generic version of Vemlidy available in the U.S., though cheaper generic alternatives like TDF and entecavir do exist. While generic TDF is significantly more affordable, the choice between it and Vemlidy often depends on an individual’s specific kidney and bone health risks. Other older options like lamivudine and adefovir are available but are no longer considered first-line treatments.
Warnings:
Vemlidy includes a boxed warning regarding the risk of severe HBV exacerbation if the medication is discontinued, requiring close monitoring after stopping. Patients must be tested for HIV before starting, as using Vemlidy alone in someone with HIV can lead to drug resistance. Additional rare but serious risks include lactic acidosis, liver enlargement, and potential new or worsening renal impairment.
Vemlidy costs approximately $1,400–$1,700 per 30-day supply. Generic tenofovir disoproxil fumarate (TDF) — an older but related HBV antiviral — is dramatically cheaper, often $20–$60/month with a coupon. Through AffordMyPrescriptions, qualifying patients receive Vemlidy at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Both are tenofovir-based HBV antivirals. Vemlidy uses tenofovir alafenamide (TAF) — newer, with less kidney and bone toxicity. Generic Viread (TDF) uses tenofovir disoproxil fumarate (TDF) — older but now available as a generic at much lower cost. For patients with normal kidney function and no osteoporosis risk, generic TDF can be a clinically equivalent and much cheaper option. For patients with kidney impairment, low bone density, or older age, Vemlidy may be preferred for safety
Tenofovir is also active against HIV. If you have undiagnosed HIV and start Vemlidy alone, the HIV could develop resistance to tenofovir — limiting future HIV treatment options. HIV testing is required before starting Vemlidy to ensure HIV is either absent or treated with combination therapy.
No, not without your hepatologist’s guidance. Stopping HBV antiviral therapy — even with undetectable HBV DNA — can cause severe acute HBV exacerbation in some patients, including liver failure. Most patients with chronic HBV remain on therapy long-term. If discontinuation is being considered, it requires careful clinical evaluation and close monitoring.
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays you cannot afford
Vemlidy has fewer significant drug interactions than many HIV regimens. However, certain rifamycins (rifampin, rifabutin), strong P-gp inducers (carbamazepine, phenytoin, phenobarbital, oxcarbazepine, St. John’s wort) can lower TAF levels. Tell your prescriber about all medications and supplements.
If denied, we explore alternatives — switching to generic tenofovir disoproxil fumarate or generic entecavir, the manufacturer’s copay program for commercially insured patients, or independent foundations. If we cannot find a path, you won’t be charged our service fee.
If you are struggling with the high cost of Vemlidy, our team may be able to help you access assistance programs — or guide you to generic tenofovir or entecavir if appropriate. Check your eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.